gene

C3

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about C3: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

603Connections

19Hypotheses

27Analyses

50Outgoing

50Incoming

19Experiments

20Debates

Summary

C3 is a gene implicated in neurodegeneration research. Key relationships include: co discussed, associated with, activates. Associated with ALS, ALZHEIMER'S DISEASE, ALZHEIMERS_DISEASE. Connected to 138 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	C3
Full Name	C3 — Complement Component 3
Aliases	Complement Component 3
Chromosome	19p13.3
Protein Type	Signaling Protein
Target Class	Signaling Protein
Function	Small molecule inhibitor of complement activation or convertase activity
Mechanism of Action	Small molecule inhibitor of complement activation or convertase activity
Druggability	Medium (0.50)
Clinical Stage	Approved
Molecular Weight	110 kDa
Amino Acids	663 aa
Exons	41
Pathways	C1q / complement-mediated synapse elimination, Complement System Activation, Complement-Mediated Microglial Engulfment, Synaptic Pruning
UniProt ID	P01024
NCBI Gene ID	735
GeneCards	C3
Human Protein Atlas	C3
Associated Diseases	A1 astrocyte transition, Alzheimer's disease, Alzheimer's_disease, Astrocyte-mediated neurotoxicity
Known Drugs/Compounds	CR2_CRRY, curcumin, dimethyl fumarate, Pegcetacoplan, resveratrol
Interactions	ADIPOQ, ALPHA_SYN, AMYLOID, AMYLOID_BETA, APOA1, APOE
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Engineered Anti-Complement Synaptic Tags Astrocyte Subtype-Specific Anti-Inflammatory Repro
KG Connections	603 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure Comparison — C3 Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

2A74 — X-ray / Cryo-EM

🔮 AI Predicted Structure

P01024 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    C3["C3"] -->|"associated"| neurodegeneration["neurodegeneration"]
    C3["C3"] -->|"interacts"| C1Q["C1Q"]
    C3["C3"] -->|"co discussed"| PLA2G4A["PLA2G4A"]
    C1Q_1["C1Q"] -->|"interacts"| C3["C3"]
    BMAL1["BMAL1"] -->|"co discussed"| C3["C3"]
    HK2["HK2"] -->|"co discussed"| C3["C3"]
    MIRO1["MIRO1"] -->|"co discussed"| C3["C3"]
    style C3 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (421)

Target	Relation	Type	Str
CR3	associated_with	receptor	1.00
C3A	encodes	protein	1.00
Neuroinflammation	associated_with	process	0.95
Microglial Phagocytosis	mediates	process	0.95
NEURODEGENERATION	promotes	process	0.95
NEUROINFLAMMATION	promotes	process	0.95
Alternative Complement Pathway	component_of	pathway	0.95
complement cascade	involved_in	pathway	0.95
Parkinson's Disease	associated_with	disease	0.95
A1 astrocyte transition	causes	phenotype	0.90
oxidative stress response	participates_in	pathway	0.90
ASTROCYTE	secreted_by	cell_type	0.90
Neurodegeneration	causes	process	0.90
astrocytes	expressed_in	cell_type	0.90
Neuroprotective Astrocyte Reactivity	biomarker_for	phenotype	0.90
C3Ar	activates	receptor	0.90
Astrocytes	expressed_in	cell_type	0.90
NF-kB signaling	participates_in	pathway	0.90
synaptic pruning	causes	process	0.90
microglia	activates	cell_type	0.90
neurons	activates	cell_type	0.90
astrocytes	activates	cell_type	0.90
Astroglia	expressed_in	cell_type	0.90
C3A	product_of	protein	0.90
complement cascade	participates_in	pathway	0.90
microglia	interacts_with	cell_type	0.90
astrocytes	inhibits	cell_type	0.90
Dopaminergic Neuron Loss	causes	phenotype	0.90
Phosphorylated α-Synuclein	upregulates	biomarker	0.88
Phagoptosis	associated_with	process	0.88
C3AR	interacts_with	protein	0.87
Microglial Activation	upregulates	process	0.85
Synaptic Pruning	involved_in	process	0.85
Phagoptosis	mediates	process	0.85
TREM2	activates_parallel	gene	0.85
Complement-Mediated Microglial Engulfment	involved_in	process	0.85
Alzheimer'S Disease	biomarker_for	disease	0.85
Microglia	activates	cell_type	0.85
Synapse Loss	promotes	phenotype	0.85
Glaucoma	involved_in	disease	0.85
MICROGLIA	activates	cell_type	0.85
DAM microglia	expressed_in	cell_type	0.85
Neurotoxic Astrocyte Reactivity	biomarker_for	phenotype	0.85
Synapse Loss	involved_in	phenotype	0.85
Complement System Activation	involved_in	process	0.85
Retinal Ganglion Cell Death	promotes	phenotype	0.85
INHIBITORY_SYNAPSE	disrupts	gene	0.80
Cognitive decline	impairs	process	0.80
Immune Cell Recruitment	associated_with	process	0.80
α-synuclein	exacerbates	protein	0.80

Incoming (182)

Source	Relation	Type	Str
h-immunity-6e54942b	relates_to	hypothesis	0.00
MICROGLIA	associated_with	cell_type	1.00
MICROGLIA	activates	cell_type	1.00
ALZHEIMER'S DISEASE	associated_with	disease	1.00
NF-KB	associated_with	protein	0.98
NFKB1	activates	gene	0.95
NFKB	regulates	protein	0.94
α-Synuclein Preformed Fibrils	upregulates	compound	0.92
A1 Reactive Astrocytes	upregulates	phenotype	0.92
A1 Astrocytes	associated_with	phenotype	0.90
NEUROINFLAMMATION	upregulates	process	0.90
Alternative Complement Pathway	activates	pathway	0.90
Lps	upregulates	compound	0.90
A1 Reactive Astrocytes	associated_with	phenotype	0.90
h-538dfc70	targets_gene	hypothesis	0.90
C4B	activates	gene	0.90
Reactive Astrocytes	upregulates	cell_type	0.90
ASTROCYTES	associated_with	cell_type	0.90
PARKINSON'S DISEASE	associated_with	disease	0.90
h-494861d2	targets	hypothesis	0.90
h-58e4635a	targets	hypothesis	0.90
SNCA	upregulates	protein	0.88
Astrocytes	product_of	cell_type	0.88
NF-ΚB	regulates	protein	0.85
APP	upregulates	gene	0.85
NF-ΚB	upregulates	protein	0.85
CYTOKINES	upregulates	protein	0.85
AMYLOID	associated_with	protein	0.82
ASTROCYTES	activates	cell_type	0.82
h-3616325a	targets	hypothesis	0.80
ASTROGLIA	expresses	cell_type	0.80
Proinflammatory Factors	upregulates	biomarker	0.80
CLU	inhibits	protein	0.80
TREM2	upregulates	gene	0.80
MICROGLIA	expresses	gene	0.80
DAMPS	sustains	process	0.80
ASTROCYTES	inhibits	cell_type	0.74
MICROGLIA	inhibits	cell_type	0.74
CANCER_CELLS	expressed_in	cell_type	0.72
C1Q	activates	protein	0.72
CR2_CRRY	inhibits	drug	0.72
ASTROCYTE	expressed_in	cell_type	0.72
HYPOXIA	activates	phenotype	0.72
Il-1Β	upregulates	protein	0.70
HMGB1	enhances	gene	0.70
PDE4B	regulates	gene	0.70
BST2	enhances	gene	0.70
Pegcetacoplan	inhibits	drug	0.70
C1Q	interacts_with	gene	0.68
TNF	associated_with	gene	0.66

Targeting Hypotheses (19)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Selective HDAC3 Inhibition with Cognitive Enhancement	0.779	neurodegeneration	Epigenetic reprogramming in aging neuron
Astrocyte C3aR Signaling as Bifurcation Point for A1/A2 Fate	0.749	alzheimers-disease-parkinsons	-
Excessive C1q/C3/CR3 complement cascade activation initiates	0.720	neurodegeneration	Synaptic pruning by microglia in neurode
HDAC3-Selective Inhibition for Clock Reset	0.710	neurodegeneration	Epigenetic clocks and biological aging i
Complement C1q/C3 Inhibition to Prevent Synaptodendritis in	0.690	neurodegeneration	Test

C3aR Blockade Disrupts the Microglial-Astrocyte Feedforward	0.651	neuroinflammation	What molecular mechanisms determine whet
Butyrate-Producing Commensal Depletion Creates Vicious Cycle	0.630	neurodegeneration	How does gut microbiome dysbiosis contri
CX3CR1-Targeted HDAC3 Knockdown in Microglia via AAV9 Delive	0.620	pharmacology	How can CNS-selective HDAC/DNMT inhibito
Complement C1q/C3 Blockade for Alzheimer's Disease	0.619	neurodegeneration	Test
Complement Cascade Specificity: Microglial C3aR Antagonism D	0.618	synaptic-biology	Does SPP1-mediated synaptic engulfment r
HDAC3-Dependent A1 Astrocyte Commitment Window	0.611	neurodegeneration	What is the optimal therapeutic window d
Systemic IL-6–STAT3–Hepatic C3 Axis and BBB-Mediated Complem	0.540	neuroinflammation	How does sevoflurane-induced NF-κB activ
Aggregation-prone sequences trigger HSP90-dependent conforma	0.497	protein-biochemistry	Do chaperones selectively recognize path
PINK1/PARK2-LC3 Mitophagy Enhancement	0.485	neuroinflammation	Immune atlas neuroinflammation analysis
Circulating hs-CRP as Disease-Modifying Target via Astrocyti	0.387	immunomics	Systemic immune profiling in neurodegene
HSP90-CDC37 complex recognizes exposed hydrophobic clusters	0.380	protein-biochemistry	Do chaperones selectively recognize path
Astrocyte Subtype-Specific Anti-Inflammatory Reprogramming	0.000	-	Cell type vulnerability in Alzheimers Di
Engineered Anti-Complement Synaptic Tags	0.000	-	Synaptic pruning by microglia in early A
Complement C3/C3aR Synaptic Protection Therapy	0.000	-	Immune atlas neuroinflammation analysis

Mentioning Analyses (27)

Scientific analyses that reference this entity

Methodology challenge: dataset 'Allen Brain SEA-AD Single Cell Dataset' — evalua

neurodegeneration | 2026-04-28 | 7 hypotheses Top: 0.662

Does tau dendritic missorting persist independently after Aβ clearance, maintain

neurodegeneration | 2026-04-25 | 7 hypotheses Top: 0.740

What signals trigger microglia to specifically recognize and phagocytose LC axon

neuroinflammation | 2026-04-14 | 0 hypotheses

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.682

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

neurodegeneration | 2026-04-12 | 0 hypotheses

Experiments (19)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Epigenetic clocks association with brain aging patterns in older women	exploratory	cognitive impairment and demen	0.900	0.00	human patients	proposed	N/A
PINK1 mutation carriers frequently report experiencing pain.	genetic_association	Parkinson's disease	0.500	0.00	human	extracted	N/A
Evidence regarding pain in DNAJC6 pathogenic variants is limited and i	genetic_association	Parkinson's disease	0.500	0.00	human	extracted	N/A
Identification of a vulnerable subtype of dopaminergic neurons co-expr	genetic_association	Parkinson's disease	0.500	0.00	mouse	extracted	N/A
Evidence regarding pain in SYNJ1 pathogenic variants is limited and in	genetic_association	Parkinson's disease	0.500	0.00	human	extracted	N/A
Anxa1+ DANs show selective earlier loss compared to other dopaminergic	neuropathology	Parkinson's disease	0.500	0.00	mouse	extracted	N/A
Released prosaposin (PSAP) was shown to induce interleukin-6 (IL-6) up	cell_biology	Parkinson's disease	0.500	0.00	cell_culture	extracted	N/A
Evidence regarding pain in FBXO7 pathogenic variants is limited and in	genetic_association	Parkinson's disease	0.500	0.00	human	extracted	N/A
Evidence regarding pain in ATP13A2 pathogenic variants is limited and	genetic_association	Parkinson's disease	0.500	0.00	human	extracted	N/A
Inhibition of transmitter release specifically in Anxa1+ neurons was s	animal_model	Parkinson's disease	0.500	0.00	mouse	extracted	N/A
Identified a subtype of Sox6+ Anxa1+ dopaminergic neurons that are sel	neuropathology	Parkinson's disease	0.500	0.00	mouse	extracted	N/A
Proposed experiment from debate on Epigenetic clocks and biological ag	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000
Animal Model Comparison for Neurodegenerative Disease Therapeutics	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,100,000
Epigenetic Dysregulation in Huntington's Disease — Therapeutic Targeti	validation	Neurodegeneration	0.400	0.50	human	completed	$3,000,000
Epigenetic Dysregulation Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000
Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disea	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000
Proposed experiment from debate on Microglia activate astrocytes via I	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
CRISPR Gene Correction Approaches for CBS/PSP	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Effect of Electronic Prescribing Compared to Paper-Based (Handwritten) Prescribi [PMID:34433219]	Aluga D, Nnyanzi LA, King N, Okolie EA,	Appl Clin Inform	2021	1
Structurally diverse sesquiterpenoids from the aerial parts of Artemisia annua ( [PMID:32891001]	Qin DP, Li HB, Pang QQ, Huang YX, Pan DB	Bioorg Chem	2020	1
Mycobacterium Abscessus: A Rare Cause of Peri-Ductal Mastitis in Endemic Regions [PMID:32580856]	Shaikh A, Vohra LM	J Coll Physicians Surg Pak	2020	1
The scanning ion conductance microscope for cellular physiology. [PMID:23086993]	Lab MJ, Bhargava A, Wright PT, Gorelik J	Am J Physiol Heart Circ Physio	2013	1
Telomere dysfunction causes sustained inflammation in chronic obstructive pulmon [PMID:21885626]	Amsellem V, Gary-Bobo G, Marcos E, Maitr	Am J Respir Crit Care Med	2011	1
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's diseas [PMID:21102463]	Franke A, McGovern DP, Barrett JC, Wang	Nat Genet	2010	1
HDAC3 Preserves the primordial follicle reserve by epigenetically suppressing fe [PMID:41803516]	["Chen Z", "Guo J", "Gao M", "Wang H", "	Cellular and molecular life sc	2026	0
Determination of the effects of [PMID:41823023]	["Yir\u00fcn A", "\u00c7ak\u0131r D", "E	Journal of Alzheimer's disease	2026	0
Discovery of a Covalent HDAC3 Degrader with Excellent Anti-Inflammatory Activity [PMID:41812251]	["Qin H", "Shi Y", "Liu R", "Wang B", "G	Journal of medicinal chemistry	2026	0
Myeloid HDAC3 deletion protects against traumatic optic injury. [PMID:41851071]	Shahror RA, Morris CA, Cunningham A, Chu	Cell death discovery	2026	0
HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis [PMID:41023273]	Mitchell CD, Morris CA, Wild M, Cunningh	Acta Pharmacol Sin	2026	0
Metabolomics identifies riboflavin as a therapeutic agent for acute pancreatitis [PMID:41352543]	Shi Y, Peng J	J Nutr Biochem	2026	0
β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708]	Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et	Acta Pharmacol Sin	2026	0
SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibi [PMID:41736683]	Wen T, Yang L, Cai S, Liu Y, Fan J et al	Adv Sci (Weinh)	2026	0
Histone deacetylases: Function in tumor development and therapeutic prospects (R [PMID:41783166]	Lin R, Zhang Y, Li H, Liang F	Oncol Lett	2026	0
LncRNA SNHG5 promotes macrophage lipid accumulation and aggravates atheroscleros [PMID:41844502]	Liu X, Wang HH, Lan XY, Sun SY, Xu XD, H	Biochimica et biophysica acta.	2026	0
HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable [PMID:41912135]	Jiang Y, Cheng S, Zhang CY, Jin X, Li L,	Cancer letters	2026	0
Histone Deacetylases Are Required for Aedes aegypti Female Reproduction and Embr [PMID:41764745]	["Balasubramani S", "Palli S"]	Archives of insect biochemistr	2026	0
Microglial HDAC3 inhibits the migration of CD8-positive T cell in the developmen [PMID:41888851]	Na Che; Yang Zhang; Bo Wang; Hongxing Wu	Cell & bioscience	2026	0
GR/HDAC3 Regulates Npas4 Signaling Pathway and Mediates Cognitive Impairment in [PMID:41837847]	Zhao Z, Song Y, Yu X, Gao Q, Wang B, Sun	FASEB journal : official publi	2026	0

Debates (20)

Multi-agent debates referencing this entity

Second debate: Microglial TREM2-SYK Pathway Enhancement

closed · Rounds: 4 · Score: 0.57 · 2026-04-28

Methodology challenge: dataset 'Allen Brain SEA-AD Single Cell Dataset' — evalua

closed · Rounds: 4 · Score: 0.76 · 2026-04-28

Debate: LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin

closed · Rounds: 4 · Score: 0.12 · 2026-04-27

Debate: ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P

closed · Rounds: 4 · Score: 0.42 · 2026-04-27

Debate: LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Debate: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes

closed · Rounds: 4 · Score: 0.47 · 2026-04-27

Debate: Microglial TREM2 downregulation impairs damage-associated response in la

closed · Rounds: 4 · Score: 0.21 · 2026-04-27

Should '40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Sele

closed · Rounds: 4 · Score: 0.52 · 2026-04-27

Should 'ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matt

closed · Rounds: 4 · Score: 0.72 · 2026-04-27

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Related Research

Hypotheses and analyses mentioning C3 in their description or question text

C3

Understanding Entity Pages

Summary

Wiki Pages (21)

Complement Component 3 (C3)

SLC30A3 — Solute Carrier Family 30 Member 3 (ZnT3)

MAP1LC3A Gene

SLC39A4 (ZIP4)

HERC3 — HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 3

SLC39A1 — Solute Carrier Family 39 Member 1

SLC39A12 — Solute Carrier Family 39 Member 12 (ZIP12)

SLC30A5 — Solute Carrier Family 3 Member 0A5 (SLC30A5)

BBC3 — BCL2 Binding Component 3 (PUMA)

HSP90 Co-chaperone CDC37 Modulation

SLC39A6 — Solute Carrier Family 39 Member 6

RAPGEF1 — Rap Guanine Nucleotide Exchange Factor 1 (C3G)

BBC3

SLC30A1

C3 Protein (Complement Component 3)

Complement C3/C5 Inhibitor Therapy

SIGLEC3 Gene (CD33)

SLC39A14 — Solute Carrier Family 39 Member 14 (Zip14)

PIK3C3 (VPS34) Protein

PIK3C3 — Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (VPS34)

SLC34A3 — Sodium-Phosphate Transporter 3

Pathway Diagram

Outgoing (421)

Incoming (182)

Targeting Hypotheses (19)

Mentioning Analyses (27)

Methodology challenge: dataset 'Allen Brain SEA-AD Single Cell Dataset' — evalua

Does tau dendritic missorting persist independently after Aβ clearance, maintain

What signals trigger microglia to specifically recognize and phagocytose LC axon

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

Which neural cell types exhibit the most pronounced gene expression alterations

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-speci

How does sevoflurane-induced NF-κB activation specifically trigger complement ca

Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo

Metabolomic signatures of neurodegeneration and energy metabolism dysfunction

Neuroinflammation and microglial priming in early Alzheimer's Disease

Neuroinflammation and microglial priming in early Alzheimer's Disease

SEA-AD Single-Cell Analysis: Cell-Type Vulnerability in Alzheimer's Disease

Which cell types show the most significant expression changes for neurodegenerat

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Immune atlas neuroinflammation analysis in neurodegeneration

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

Cell type vulnerability debate in Alzheimer's disease (SEA-AD v4)

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Metabolic reprogramming in neurodegenerative disease

Synaptic pruning by microglia in early AD

Senolytic therapy for age-related neurodegeneration

Microglia-astrocyte crosstalk amplification loops in neurodegeneration

Astrocyte reactivity subtypes in neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

Experiments (19)

Related Papers (20)

Debates (20)

Second debate: Microglial TREM2-SYK Pathway Enhancement

Methodology challenge: dataset 'Allen Brain SEA-AD Single Cell Dataset' — evalua

Debate: LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin

Debate: ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P

Debate: LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i

Debate: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes

Debate: Microglial TREM2 downregulation impairs damage-associated response in la

Should '40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Sele

Should 'ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matt

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

Related Research

C3aR Blockade Disrupts the Microglial-Astrocyte Feedforward Neurotoxic Loop

Butyrate-Producing Commensal Depletion Creates Vicious Cycle: HDAC3 Overactivity

CX3CR1-Targeted HDAC3 Knockdown in Microglia via AAV9 Delivery

Complement C1q/C3 Blockade for Alzheimer's Disease

Complement Cascade Specificity: Microglial C3aR Antagonism Downstream of SPP1

HDAC3-Dependent A1 Astrocyte Commitment Window

Systemic IL-6–STAT3–Hepatic C3 Axis and BBB-Mediated Complement Translocation

Aggregation-prone sequences trigger HSP90-dependent conformational triage throug

PINK1/PARK2-LC3 Mitophagy Enhancement